Breast cancer was first referred in literature in the ancient era, by the Egyptians on the slaves that were refining oil, later after the abolition of this institute and modernization of the society during the XIX-XX th century it was regarded as a distinct condition that is harmful for the health and quality of life (QOL). Halsted’s radical mastectomy is the dominant treatment method in malignant states with a pharmacological approach in benign lesions. We identified hereditary (BSCS, FOXA, GATA-3, P-REX1, HP-1β, BRCA1, BRCA2, p53, HOXD10, KLF4, PTEN and k-RAS), molecular (uPA/PAI1, ER, PR, ERBB2, Ki-67, CA-15-3, CA-27.29, luminal A, luminal B, HSP-27, PD-L1, PIK3CA) and prognostic markers (TIL, mRNA and microRNA). The targeted therapy consisted of ER, PR and Ki-67 targeting with tamoxifen, anastrozole and exemestane with and additional load of monoclonal antibodies (transtuzumab, pertuzumab, lapatinib, neratinib and transtuzumab emtasidin). Bimodal doses that are dependent on maturity (21-23 years old or younger) of upamostat are regarded in uPA-PAI1 system disbalances. Luminal A subtype regards mTOR (anastrozole, exemesta everolimus/exemestane), CDK4/6 (palbociclib, ribociclib and abemaciclib) and PI3K (alpelisib and GDC-077) along with the luminal B subtypes that is managed via triptorelin and nivolumab. Breast cancer with HSP-27 sensible expression has an experimental management using first generation brivudine, quercetine, J2-crosslinker and second generation OGX427, PA11 and PA50. The PD-L1 subtype is sensibile to monoclonal antibodies (pembrolizumab, atezolizumab, avelumab) in conjunction with eribuline, paclitaxel and capecitabine. The PI3CKA mutation is a protective mutation. The most regarded BRCA1/BRCA2 mutations are manageable with olaparib. The research regarding the non-surgical treatment of breast cancer is highly regarded internationally due to the highly traumatic and painful process of the radical mastectomy. Radiotherapeuthical approaches are not deemed to become successful in favor of the breast cancer pharmacotherapy thus employing the need to create ind chemotherapeutical approaches in breast cancer. Breast cancer is a heterogeneous condition with a personalized and individual takeover on a genetic approach compared to the absolute indication of radical mastectomy in general surgery.